| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
6,130,000 |
| Market
Cap: |
1.71(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2787 - $0.2787 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products that address unmet medical needs in the treatment of cardiopulmonary diseases. Co.'s focus is the continued development of its nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using its proprietary pulsatile nitric oxide delivery platform, INOpulse. Co.'s INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide. Co. is developing its INOpulse for the treatment of patients with fibrotic interstitial lung disease at a risk for pulmonary hypertension.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
1,211,262 |
1,780,717 |
| Total Sell Value |
$0 |
$0 |
$223,345 |
$5,615,495 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
2 |
4 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Abrams David |
Treasurer |
• – – |
2015-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,116 |
13,116 |
|
- |
|
| Peacock Jonathan M |
President and CEO |
• • – |
2015-08-19 |
4 |
B |
$5.48 |
$27,377 |
D/D |
5,000 |
31,427 |
2.81 |
- |
|
| Peacock Jonathan M |
President and CEO |
• • – |
2015-05-20 |
4 |
B |
$8.69 |
$48,323 |
D/D |
5,560 |
26,427 |
2.81 |
- |
|
| Meglasson Martin |
Chief Scientific Officer |
• – – |
2015-05-20 |
4 |
B |
$8.40 |
$5,981 |
D/D |
712 |
19,098 |
2.74 |
- |
|
| Fernandes Peter |
Chief Regulatory OfficerOffice |
• – – |
2015-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,395 |
|
- |
|
| Peacock Jonathan M |
President and CEO |
• • – |
2015-02-19 |
4 |
B |
$12.00 |
$249,600 |
D/D |
20,800 |
20,867 |
2.81 |
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2015-02-19 |
4 |
B |
$12.00 |
$2,551,992 |
D/D |
212,666 |
965,660 |
2.45 |
- |
|
| Klinsky Steven B |
10% Owner |
– – • |
2015-02-19 |
4 |
B |
$12.00 |
$12,841,992 |
D/D |
1,070,166 |
4,859,885 |
2.45 |
- |
|
| Weinstein Adam |
Director |
– • • |
2015-02-19 |
4 |
B |
$12.00 |
$12,841,992 |
I/I |
1,070,166 |
4,859,885 |
2.25 |
- |
|
| Nelsen Robert |
Director |
– • • |
2015-02-19 |
4 |
B |
$12.00 |
$2,551,992 |
I/I |
212,666 |
965,660 |
2.25 |
- |
|
| Holt Matthew S. |
Director |
– • • |
2015-02-19 |
4 |
B |
$12.00 |
$12,841,992 |
I/I |
1,070,166 |
4,859,885 |
2.25 |
- |
|
| Linde North America, Inc. |
10% Owner |
– – • |
2015-02-19 |
4 |
B |
$12.00 |
$4,306,992 |
D/D |
358,916 |
1,629,804 |
2.45 |
- |
|
| Meglasson Martin |
Chief Scientific Officer |
• – – |
2015-02-19 |
4 |
B |
$12.00 |
$144,000 |
D/D |
12,000 |
18,386 |
2.74 |
- |
|
| Luehring Jens |
Director |
– • • |
2015-02-19 |
4 |
B |
$12.00 |
$4,306,992 |
I/I |
358,916 |
1,629,804 |
2.25 |
- |
|
| Tasse Daniel |
Director |
– • – |
2015-02-19 |
4 |
B |
$12.00 |
$300,000 |
D/D |
25,000 |
128,898 |
2.39 |
- |
|
| Heyrman Reinilde |
Chief Clinical Dev. Officer |
• – – |
2015-02-19 |
4 |
B |
$12.00 |
$18,000 |
D/D |
1,500 |
9,483 |
2.74 |
- |
|
| Naidu Manesh |
Chief Business Officer |
• – – |
2015-02-19 |
4 |
B |
$12.00 |
$18,000 |
D/D |
1,500 |
11,319 |
2.74 |
- |
|
| Weinstein Adam |
Director |
– • • |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,789,719 |
|
- |
|
| Klinsky Steven B |
10% Owner |
– – • |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,789,719 |
|
- |
|
| Linde North America, Inc. |
10% Owner |
– – • |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,270,888 |
|
- |
|
| Tasse Daniel |
Director |
– • – |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
93,336 |
|
- |
|
| Tasse Daniel |
Director |
– • – |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,562 |
|
- |
|
| Meglasson Martin |
Chief Scientific OfficerOffice |
• – – |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,991 |
|
- |
|
| Meglasson Martin |
Chief Scientific OfficerOffice |
• – – |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,395 |
|
- |
|
| Heyrman Reinilde |
Chief Clinical Dev. OfficerOff |
• – – |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,983 |
|
- |
|
188 Records found
|
|
Page 7 of 8 |
|
|
